Dutch biotech InteRNA Technologies has raised €18.5 million ($22 million) in second-round financing as it prepares to start clinical trials of its lead drug candidate INT-1B3 for solid tumours.
Planning permission has been secured to create a 60-seat dining room with a glass wall to provide panoramic views of the countryside. This is set to open early next year. Directors Matt and Alex ...